1. Home
  2. CRGY vs CRSP Comparison

CRGY vs CRSP Comparison

Compare CRGY & CRSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Crescent Energy Company

CRGY

Crescent Energy Company

N/A

Current Price

$11.62

Market Cap

5.5B

Sector

Energy

ML Signal

N/A

Logo CRISPR Therapeutics AG

CRSP

CRISPR Therapeutics AG

N/A

Current Price

$45.89

Market Cap

4.8B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
CRGY
CRSP
Founded
1986
2013
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Oil & Gas Production
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Energy
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.5B
4.8B
IPO Year
2022
2016

Fundamental Metrics

Financial Performance
Metric
CRGY
CRSP
Price
$11.62
$45.89
Analyst Decision
Buy
Buy
Analyst Count
17
23
Target Price
$18.69
★ $85.42
AVG Volume (30 Days)
★ 8.5M
1.4M
Earning Date
11-02-2026
11-02-2026
Dividend Yield
★ 4.31%
N/A
EPS Growth
★ N/A
N/A
EPS
★ N/A
N/A
Revenue
★ $3,579,782,000.00
$289,590,000.00
Revenue This Year
$41.06
$910.97
Revenue Next Year
$23.05
$277.83
P/E Ratio
$99.08
★ N/A
Revenue Growth
22.14
★ 9169.85
52 Week Low
$7.68
$44.12
52 Week High
$15.47
$63.45

Technical Indicators

Market Signals
Indicator
CRGY
CRSP
Relative Strength Index (RSI) 38.19 36.78
Support Level $11.45 N/A
Resistance Level $11.69 $61.08
Average True Range (ATR) 0.53 2.66
MACD -0.25 -0.43
Stochastic Oscillator 28.67 8.12

Price Performance

Historical Comparison
CRGY
CRSP

About CRGY Crescent Energy Company

Crescent Energy Co is an energy company committed to delivering value for shareholders through disciplined growth, acquisition ideas, and the consistent return of capital. Its long-life, balanced portfolio combines stable cash flows from low-decline production with deep, high-quality development inventory. The company operates in one reportable segment, which is the exploration and production of crude oil, natural gas, and NGLs.

About CRSP CRISPR Therapeutics AG

Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.

Share on Social Networks: